12.01.2023

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

11.21.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

11.02.2023

Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting

11.02.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

10.31.2023

Pfizer Reports Third-Quarter 2023 Results

10.26.2023

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

10.20.2023

FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

10.13.2023

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance

10.13.2023

U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

10.12.2023

U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

10.05.2023

Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases

10.04.2023

Pfizer Declares Fourth-Quarter 2023 Dividend